TALC
Clinical safety rating: caution
Comprehensive clinical and safety monograph for TALC (TALC).
Talc (magnesium silicate) induces pleural fibrosis and adhesion by causing an inflammatory response and fibroblast proliferation, leading to symphysis of the pleural layers.
| Metabolism | Not metabolized; inert substance. Cleared by lymphatic drainage and phagocytosis by macrophages. |
| Excretion | Talc is not absorbed systemically; elimination is primarily via fecal excretion of the unabsorbed material. In cases of pleural administration, talc particles are cleared by lymphatic drainage and may be phagocytized by macrophages; no significant renal or biliary excretion occurs. |
| Half-life | Not applicable; talc is a non-absorbable material. No systemic half-life exists; local persistence in pleural space can be months to years. |
| Protein binding | Not applicable; talc does not bind to plasma proteins as it is not systemically absorbed. |
| Volume of Distribution | Not applicable; talc remains at site of administration (pleural space, lungs) or in GI tract; no systemic distribution. |
| Bioavailability | Oral: negligible (<0.1%); inhalation: minimal systemic absorption; intrapleural: not systemically available. |
| Onset of Action | Intrapleural administration: 24-72 hours for pleurodesis effect; inhalation: immediate mechanical irritation, with clinical effects (cough, dyspnea) occurring within minutes to hours. |
| Duration of Action | Pleurodesis: weeks to permanent; inhaled talc effects may last hours to days, residual pleural fibrosis permanent. |
Intrapleural administration: 5 g mixed with 250 mL normal saline instilled via chest tube, followed by clamping for 1 hour then drainage.
| Dosage form | POWDER |
| Renal impairment | No dose adjustment required; talc is not significantly renally eliminated. |
| Liver impairment | No dose adjustment required. |
| Pediatric use | Not established; safety and efficacy in children have not been determined. |
| Geriatric use | No specific dose adjustment; use with caution due to potential comorbidities and reduced pulmonary reserve. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for TALC (TALC).
| Breastfeeding | Talc is not absorbed systemically; topical use considered safe during breastfeeding. No M/P ratio available as systemic levels are negligible. |
| Teratogenic Risk | No known teratogenic risk; talc is not absorbed systemically when applied topically or used perineally. No fetal harm reported in any trimester. |
| Fetal Monitoring | No specific monitoring required due to lack of systemic absorption. |
■ FDA Black Box Warning
None
| Serious Effects |
["Hypersensitivity to talc","Uncontrolled infection at the site of administration","Bronchopleural fistula","Pregnancy (relative)"]
| Precautions | ["Risk of acute respiratory distress syndrome (ARDS) and pneumonitis due to systemic absorption","Hypersensitivity reactions including anaphylaxis","Fever and chest pain common post-procedure","Do not use in patients with extensive pleural fibrosis or trapped lung"] |
Loading safety data…
| Fertility Effects | No known effects on fertility from topical use. Intraperitoneal talc (as in pleurodesis) may cause pelvic adhesions reducing fertility in women. |